Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma

Dr. Daud on the Combinations of Immunotherapy for MelanomaПодробнее

Dr. Daud on the Challenges of Treating Metastatic Melanoma With BRAF Inhibitor MonotherapyПодробнее

Dr. Daud Discusses the Immunogenicity of MelanomaПодробнее

FDA Approval of Adjuvant Dabrafenib/Trametinib in BRAF+ MelanomaПодробнее

Dr. Daud Discusses the Current Status of Immunotherapy in MelanomaПодробнее

BGB324 With Pembrolizumab or Dabrafenib/Trametinib in MelanomaПодробнее

Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in MelanomaПодробнее

Immunotherapy Versus Targeted Therapy for Advanced MelanomaПодробнее

Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With MelanomaПодробнее

Activity of Dabrafenib/Trametinib Combo in Patients With Melanoma Brain MetastasesПодробнее

Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated MelanomaПодробнее

Dr. Wilson on Long-term Data With Dabrafenib Plus Trametinib in MelanomaПодробнее

Dabrafenib and trametinib: a promising combination for the treatment of melanomaПодробнее

Adverse Events With Dabrafenib/Trametinib Combination in MelanomaПодробнее

Five-Year OS Data for Dabrafenib/Trametinib Combo in MelanomaПодробнее

Adil Daud, MD: Optimal Sequencing for BRAF-Mutant Melanoma PatientsПодробнее

Dr. Long on Dabrafenib/Trametinib in BRAF V600E-Mutant MelanomaПодробнее

Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in MelanomaПодробнее

Dr. Robert on 5-Year Analysis of Dabrafenib/Trametinib in BRAF V600-Mutant MelanomaПодробнее